Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Mercuri

Showing results (81-90 of 96) with videos related to

Pageof 10
Sort By:
Circulation. Cardiovascular Quality and Outcomes|June 3, 2024
Application of the Win Ratio Method in the ENGAGE AF-TIMI 48 Trial Comparing Edoxaban With Warfarin in Patients With Atrial FibrillationBrian A Bergmark, Jeong-Gun Park, Rose A Hamershock, et al.
Lancet (London, England)|March 15, 2015
Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trialJessica L Mega, Joseph R Walker, Christian T Ruff, et al.
Journal of the American College of Cardiology|July 13, 2019
Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver DiseaseArman Qamar, Elliott M Antman, Christian T Ruff, et al.
Stroke|July 9, 2016
Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48)Natalia S Rost, Robert P Giugliano, Christian T Ruff, et al.
Circulation Reports|May 11, 2026
Efficacy and Safety of Acoramidis in Japanese Adults With Symptomatic Transthyretin Amyloid CardiomyopathyJin Endo, Kenichi Tsujita, Chisato Izumi, et al.
The New England Journal of Medicine|May 22, 2023
Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin AmyloidPablo Garcia-Pavia, Fabian Aus dem Siepen, Erwan Donal, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|June 29, 2019
Direct Oral Anticoagulants for Pulmonary Embolism: Importance of Anatomical ExtentMarjolein P A Brekelmans, Harry R Büller, Michele F Mercuri, et al.
Thrombosis and Haemostasis|December 7, 2017
Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE StudyAndria Medina, Gary Raskob, Walter Ageno, et al.
Thrombosis Research|December 18, 2017
Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trialThomas Vanassche, Peter Verhamme, Philip S Wells, et al.
Lancet (London, England)|September 4, 2016
Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trialAndreas Goette, Jose L Merino, Michael D Ezekowitz, et al.
Pageof 10

Showing results (81-90 of 96) with videos related to

Sort By:
Pageof 10
Circulation. Cardiovascular Quality and Outcomes|June 3, 2024
Application of the Win Ratio Method in the ENGAGE AF-TIMI 48 Trial Comparing Edoxaban With Warfarin in Patients With Atrial FibrillationBrian A Bergmark, Jeong-Gun Park, Rose A Hamershock, et al.
Lancet (London, England)|March 15, 2015
Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trialJessica L Mega, Joseph R Walker, Christian T Ruff, et al.
Journal of the American College of Cardiology|July 13, 2019
Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver DiseaseArman Qamar, Elliott M Antman, Christian T Ruff, et al.
Stroke|July 9, 2016
Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48)Natalia S Rost, Robert P Giugliano, Christian T Ruff, et al.
Circulation Reports|May 11, 2026
Efficacy and Safety of Acoramidis in Japanese Adults With Symptomatic Transthyretin Amyloid CardiomyopathyJin Endo, Kenichi Tsujita, Chisato Izumi, et al.
The New England Journal of Medicine|May 22, 2023
Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin AmyloidPablo Garcia-Pavia, Fabian Aus dem Siepen, Erwan Donal, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|June 29, 2019
Direct Oral Anticoagulants for Pulmonary Embolism: Importance of Anatomical ExtentMarjolein P A Brekelmans, Harry R Büller, Michele F Mercuri, et al.
Thrombosis and Haemostasis|December 7, 2017
Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE StudyAndria Medina, Gary Raskob, Walter Ageno, et al.
Thrombosis Research|December 18, 2017
Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trialThomas Vanassche, Peter Verhamme, Philip S Wells, et al.
Lancet (London, England)|September 4, 2016
Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trialAndreas Goette, Jose L Merino, Michael D Ezekowitz, et al.
Pageof 10